signumia
Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
PODD

Close price

$148.88

Latest price

$151.48

Change vs close

+1.75%

Current price: $151.48

Market cap

10.49B

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

Insulet Corporation

PODD

NASDAQ-GS · Health Care · Medical/Dental Instruments

Company Profile

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Website

https://www.insulet.com

Country

MA

Sector

Health Care

Industry

Medical/Dental Instruments

CIK

0001145197

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q2 Aug 2026

Quarterly Snapshot

Q2 Aug 2026

Mix

11.4B

Market cap

92.06%

10.49B

Expected quarterly revenue

7.05%

803.1M

Estimated quarterly net income

0.9%

102.19M

Market cap / expected revenue

13.06x

Revenue

Forecast

803.1M

Previous quarter

+5.44%

Net income

Forecast

102.19M

Previous quarter

+12.17%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

13 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
8-KJun 25, 2026Jun 24, 20260001145197-26-000148Document
4Jun 4, 2026Jun 3, 20260001145197-26-000143Document
4Jun 4, 2026Jun 3, 20260001145197-26-000142Document
4Jun 3, 2026Jun 3, 20260001145197-26-000138Document
144Jun 3, 2026No data0001959173-26-004306Document
SDMay 28, 2026No data0001145197-26-000136Document
8-KMay 26, 2026May 26, 20260001145197-26-000132Document
4May 21, 2026May 20, 20260001145197-26-000129Document
4May 21, 2026May 20, 20260001145197-26-000128Document
4May 21, 2026May 20, 20260001145197-26-000127Document
4May 21, 2026May 20, 20260001145197-26-000126Document
4May 21, 2026May 20, 20260001145197-26-000125Document

Latest News

12 articles
BNK InvestJun 23, 2026, 12:00 AMnasdaq

S&P 500 Movers: SNDK, AXON

In early trading on Tuesday, shares of Axon Enterprise topped the list of the day's best performing components of the S&P 500 index, trading up 4.5%. Year to date, Axon Enterprise has lost about 24.6% of its value. And the worst performing S&P 500 component thus far on

Open article
ZacksJun 16, 2026, 12:00 AMnasdaq

Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation

ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.

Open article
BNK InvestJun 8, 2026, 12:00 AMnasdaq

Monday 6/8 Insider Buying Report: PODD, ADC

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we

Open article
RTTNewsJun 8, 2026, 12:00 AMnasdaq

Insulet Presents Positive Pivotal Trial Data For Omnipod 6 And FLC In Treating Diabetes

(RTTNews) - Insulet Insult Corporation (PODD), a medical devices company, on Saturday released results for the STRIVE trial for Omnipod 6, an automated insulin delivery system, and the EVOLUTION 3 feasibility study for the fully-closed loop system in treating type-2 diabetes. The

Open article
ZacksJun 5, 2026, 12:00 AMnasdaq

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Open article
The Motley FoolJun 4, 2026, 12:00 AMnasdaq

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Key PointsDexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries.

Open article
ZacksJun 3, 2026, 12:00 AMnasdaq

Tandem Diabetes Valuation: Is 1.1x Sales a Buy?

TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.

Open article
ZacksJun 2, 2026, 12:00 AMnasdaq

TNDM Stock: What to Know About Tandem's 2026 Reset

Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.

Open article
ZacksJun 2, 2026, 12:00 AMnasdaq

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Open article
ZacksMay 28, 2026, 12:00 AMnasdaq

PODD Stock: What a Hold Rating Says at a $163 Target

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

Open article
ZacksMay 27, 2026, 12:00 AMnasdaq

PODD and Omnipod 5: What's Driving Insulet's 2026 Growth

Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

Open article
BNK InvestMay 27, 2026, 12:00 AMnasdaq

S&P 500 Movers: BSX, MGM

In early trading on Wednesday, shares of MGM Resorts International topped the list of the day's best performing components of the S&P 500 index, trading up 7.4%. Year to date, MGM Resorts International registers a 13.2% gain. And the worst performing S&P 500 component

Open article